BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 12587795)

  • 1. High-dose-rate stereotactic brachytherapy for patients with newly diagnosed glioblastoma multiformes.
    Chang CN; Chen WC; Wei KC; Ng SH; Ho YS; Huang DY; Lee SP; Hong JH
    J Neurooncol; 2003 Jan; 61(1):45-55. PubMed ID: 12587795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival following CyberKnife radiosurgery and hypofractionated radiotherapy for newly diagnosed glioblastoma multiforme.
    Lipani JD; Jackson PS; Soltys SG; Sato K; Adler JR
    Technol Cancer Res Treat; 2008 Jun; 7(3):249-55. PubMed ID: 18473497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.
    Niranjan A; Kano H; Iyer A; Kondziolka D; Flickinger JC; Lunsford LD
    J Neurosurg; 2015 Apr; 122(4):757-65. PubMed ID: 25594327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implant volume as a prognostic variable in brachytherapy decision-making for malignant gliomas stratified by the RTOG recursive partitioning analysis.
    Videtic GM; Gaspar LE; Zamorano L; Stitt LW; Fontanesi J; Levin KJ
    Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):963-8. PubMed ID: 11704318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gamma knife stereotactic radiosurgery for patients with glioblastoma multiforme.
    Nwokedi EC; DiBiase SJ; Jabbour S; Herman J; Amin P; Chin LS
    Neurosurgery; 2002 Jan; 50(1):41-6; discussion 46-7. PubMed ID: 11844233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy.
    Chan TA; Weingart JD; Parisi M; Hughes MA; Olivi A; Borzillary S; Alahakone D; Detorie NA; Wharam MD; Kleinberg L
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1133-9. PubMed ID: 15990019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.
    Prados MD; Wara WM; Sneed PK; McDermott M; Chang SM; Rabbitt J; Page M; Malec M; Davis RL; Gutin PH; Lamborn K; Wilson CB; Phillips TL; Larson DA
    Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):71-7. PubMed ID: 11163499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment outcomes for patients with glioblastoma multiforme and a low Karnofsky Performance Scale score on presentation to a tertiary care institution. Clinical article.
    Marina O; Suh JH; Reddy CA; Barnett GH; Vogelbaum MA; Peereboom DM; Stevens GH; Elinzano H; Chao ST
    J Neurosurg; 2011 Aug; 115(2):220-9. PubMed ID: 21548745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CT-guided interstitial HDR-brachytherapy for recurrent glioblastoma multiforme: a 20-year single-institute experience.
    Chatzikonstantinou G; Zamboglou N; Archavlis E; Strouthos I; Zoga E; Milickovic N; Hilaris B; Baltas D; Rödel C; Tselis N
    Strahlenther Onkol; 2018 Dec; 194(12):1171-1179. PubMed ID: 30203110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic radiosurgery as an adjunct to surgery and external beam radiotherapy in the treatment of patients with malignant gliomas.
    Gannett D; Stea B; Lulu B; Adair T; Verdi C; Hamilton A
    Int J Radiat Oncol Biol Phys; 1995 Sep; 33(2):461-8. PubMed ID: 7673034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors.
    Prados MD; Larson DA; Lamborn K; McDermott MW; Sneed PK; Wara WM; Chang SM; Mack EE; Krouwer HG; Chandler KL; Warnick RE; Davis RL; Rabbitt JE; Malec M; Levin VA; Gutin PH; Phillips TL; Wilson CB
    Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):57-63. PubMed ID: 9422558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial.
    Mirimanoff RO; Gorlia T; Mason W; Van den Bent MJ; Kortmann RD; Fisher B; Reni M; Brandes AA; Curschmann J; Villa S; Cairncross G; Allgeier A; Lacombe D; Stupp R
    J Clin Oncol; 2006 Jun; 24(16):2563-9. PubMed ID: 16735709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CT-guided interstitial HDR brachytherapy for recurrent glioblastoma multiforme. Long-term results.
    Tselis N; Kolotas C; Birn G; Röddiger S; Filipowicz I; Kontova M; Fountzilas G; Selviaridis P; Baltas D; Heyd R; Anagnostopoulos G; Zamboglou N
    Strahlenther Onkol; 2007 Oct; 183(10):563-70. PubMed ID: 17896088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: prognostic factors and long-term outcome.
    Shrieve DC; Alexander E; Black PM; Wen PY; Fine HA; Kooy HM; Loeffler JS
    J Neurosurg; 1999 Jan; 90(1):72-7. PubMed ID: 10413158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (> 20 or < or = 20 cm(2), respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients.
    Coughlin C; Scott C; Langer C; Coia L; Curran W; Rubin P
    Int J Radiat Oncol Biol Phys; 2000 Dec; 48(5):1351-8. PubMed ID: 11121633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain. CNS Cancer Consortium.
    Halperin EC; Herndon J; Schold SC; Brown M; Vick N; Cairncross JG; Macdonald DR; Gaspar L; Fischer B; Dropcho E; Rosenfeld S; Morowitz R; Piepmeier J; Hait W; Byrne T; Salter M; Imperato J; Khandekar J; Paleologos N; Burger P; Bentel GC; Friedman A
    Int J Radiat Oncol Biol Phys; 1996 Mar; 34(4):793-802. PubMed ID: 8598355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypo-fractionated IMRT for patients with newly diagnosed glioblastoma multiforme: a 6 year single institutional experience.
    Ciammella P; Galeandro M; D'Abbiero N; Podgornii A; Pisanello A; Botti A; Cagni E; Iori M; Iotti C
    Clin Neurol Neurosurg; 2013 Sep; 115(9):1609-14. PubMed ID: 23453151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival and functional status after resection of recurrent glioblastoma multiforme.
    Barker FG; Chang SM; Gutin PH; Malec MK; McDermott MW; Prados MD; Wilson CB
    Neurosurgery; 1998 Apr; 42(4):709-20; discussion 720-3. PubMed ID: 9574634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upfront boost Gamma Knife "leading-edge" radiosurgery to FLAIR MRI-defined tumor migration pathways in 174 patients with glioblastoma multiforme: a 15-year assessment of a novel therapy.
    Duma CM; Kim BS; Chen PV; Plunkett ME; Mackintosh R; Mathews MS; Casserly RM; Mendez GA; Furman DJ; Smith G; Oh N; Caraway CA; Sanathara AR; Dillman RO; Riley AS; Weiland D; Stemler L; Cannell R; Abrams DA; Smith A; Owen CM; Eisenberg B; Brant-Zawadzki M
    J Neurosurg; 2016 Dec; 125(Suppl 1):40-49. PubMed ID: 27903197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome of patients with WHO Grade III and IV gliomas treated by fractionated intracavitary radioimmunotherapy.
    Reulen HJ; Poepperl G; Goetz C; Gildehaus FJ; Schmidt M; Tatsch K; Pietsch T; Kraus T; Rachinger W
    J Neurosurg; 2015 Sep; 123(3):760-70. PubMed ID: 26140493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.